Data gathered: February 1
AI Stock Analysis - BioNTech (BNTX)
Analysis generated January 31, 2024. Powered by Chat GPT.
BioNTech SE is a German biotechnology company known for developing a range of patient-specific immunotherapies for cancer and other diseases. Co-founded by Ugur Sahin and Ozlem Tureci, BioNTech gained international recognition through its collaboration with Pfizer in developing one of the first widely authorized mRNA COVID-19 vaccines. The company operates in a rapidly evolving industry characterized by intense research and development, advanced technology platforms, and a growing pipeline of therapeutic and vaccine candidates.
Stock Alerts - BioNTech (BNTX)
 |
BioNTech | January 23 Price is up by 5.2% in the last 24h. |
|
BioNTech | January 22 Employee Rating is down by 3.1% over the last month. |
|
BioNTech | January 21 Price is up by 5.3% in the last 24h. |
|
BioNTech | January 13 Price is down by -6.2% in the last 24h. |
Alternative Data for BioNTech
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 138 | Sign up | Sign up | Sign up |
| Sentiment | 52 | Sign up | Sign up | Sign up |
| Webpage traffic | 166,000 | Sign up | Sign up | Sign up |
| Employee Rating | 62 | Sign up | Sign up | Sign up |
| Google Trends | 33 | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 8 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 18,998 | Sign up | Sign up | Sign up |
| Twitter Followers | 81,875 | Sign up | Sign up | Sign up |
| Twitter Mentions | 10 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 39 | Sign up | Sign up | Sign up |
| Linkedin Employees | 4,876 | Sign up | Sign up | Sign up |
About BioNTech
BioNTech SE is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases.
| Price | $123.77 |
| Target Price | Sign up |
| Volume | 862,700 |
| Market Cap | $29B |
| Year Range | $78.36 - $126.88 |
| Dividend Yield | 0% |
| PE Ratio | 160.8 |
| Analyst Rating | 81% buy |
| Industry | Biotechnology |
In the news
BioNTech : Modern Slavery Act Statement 2023January 28 - Finnhub |
|
 |
BioNTech SE (NASDAQ:BNTX) Position Increased by Atomi Financial Group Inc.January 25 - ETF Daily News |
 |
BioNTech SE: Lackluster Financials And Uncertainties In Product Pipeline-HoldJanuary 22 - SeekingAlpha |
|
Analysts Set BioNTech SE (NASDAQ:BNTX) Price Target at $142.72January 19 - ETF Daily News |
BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 13 - Finnhub |
|
 |
BioNTech (NASDAQ:BNTX) Earns Buy Rating from Analysts at Truist FinancialJanuary 12 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 1.24B | 179M | 1.07B | 198M | 211M | 0.880 |
| Q2 '24 | 129M | 60M | 69M | -808M | -749M | -3.360 |
| Q1 '24 | 188M | 59M | 129M | -315M | -289M | -1.410 |
| Q4 '23 | 1.48B | 179M | 1.3B | 458M | 507M | 1.900 |
| Q3 '23 | 1.48B | 179M | 1.3B | 458M | 456M | 0.670 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Joshua Gottheimer Democrat |
May 15, 24 | Buy | $1K - $15K |
| Joshua Gottheimer Democrat |
Apr 7, 24 | Sell | $1K - $15K |
| Joshua Gottheimer Democrat |
Jan 7, 24 | Buy | $1K - $15K |
Read more about BioNTech (BNTX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of BioNTech?
The Market Cap of BioNTech is $29B.
What is BioNTech's PE Ratio?
As of today, BioNTech's PE (Price to Earnings) ratio is 160.8.
What is the current stock price of BioNTech?
Currently, the price of one share of BioNTech stock is $123.77.
How can I analyze the BNTX stock price chart for investment decisions?
The BNTX stock price chart above provides a comprehensive visual representation of BioNTech's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling BioNTech shares. Our platform offers an up-to-date BNTX stock price chart, along with technical data analysis and alternative data insights.
Does BNTX offer dividends to its shareholders?
As of our latest update, BioNTech (BNTX) does not offer dividends to its shareholders. Investors interested in BioNTech should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of BioNTech?
Some of the similar stocks of BioNTech are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.